Alan Bash
Directeur Général chez Zielbio, Inc.
Postes actifs de Alan Bash
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Zielbio, Inc.
 Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Directeur/Membre du Conseil | 03/01/2023 | - |
| Directeur Général | 03/01/2023 | - |
Historique de carrière de Alan Bash
Anciens postes connus de Alan Bash
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
| CHECKMATE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/03/2022 | 31/05/2022 |
| Directeur Général | 01/03/2022 | - | |
| President | 01/03/2022 | - |
Formation de Alan Bash
| Georgetown University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| President | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 2 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Zielbio, Inc.
Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
